IP Library › Granted Patent US 12,187,796
Granted Patent B2
US 12,187,796 · App. 18/364,285 · Granted Jan 7, 2025

ILT3-binding agents and methods of use thereof

Inventors: Suzanne Christine Crawley (Brisbane, CA); Jer-Yuan Hsu (San Bruno, CA); Daniel David Kaplan (San Mateo, CA); Betty Chan Li (Millbrae, CA); Vicky Yi-Bing Lin (Cupertino, CA); Seth Malmersjö (Menlo Park, CA); Kevin James Paavola (San Francisco, CA); Julie Michelle Roda (Pacifica, CA); Yan Wang (Foster City, CA)
Assignee: NGM Biopharmaceuticals, Inc.
C07K16/2803A61K2039/505C07K2317/565
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,187,796
App. No.
18/364,285
Granted
Jan 7, 2025
Kind
B2
Abstract

The present disclosure provides binding agents, such as antibodies, that specifically bind ILT3, including human ILT3, as well as compositions comprising the binding agents, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising the binding agents.

Claims (111)

1. A binding agent that specifically binds human immunoglobulin-like transcript 3 (ILT3), comprising:

(a) a heavy chain variable region (VH) comprising a VH-complementarity determining region (CDR) 1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO: 117 and a light chain variable region (VL) comprising a VL-complementarity determining region (CDR) 1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO: 118;

(b) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO: 119 and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO:120;

(c) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO: 109 and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO:110;

(d) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO:113 and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO:114;

(e) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO:115 and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO: 116; or

(f) a VH comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3 from the amino acid sequence of SEQ ID NO: 121 and a VL comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3 from the amino acid sequence of SEQ ID NO:122.

2. The binding agent of claim 1 , wherein:

(a) the VH comprises the VH-CDR1, the VH-CDR2, and the VH-CDR3 from the amino acid sequence of SEQ ID NO:117; and the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 from the amino acid sequence of SEQ ID NO: 118, and wherein

(i) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:71, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:72, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:73, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 74, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:75, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:76;

(ii) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:77, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:78, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:73, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 74, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:75, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:76;

(iii) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:71, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:79, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:73, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 74, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:75, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:76;

(iv) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:80, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:72, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:73, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 74, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:75, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:76; or

(v) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:81, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:82, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:83, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 84, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:85, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:86; or

(b) the VH comprises the VH-CDR1, the VH-CDR2, and the VH-CDR3 from the amino acid sequence of SEQ ID NO:119; and the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 from the amino acid sequence of SEQ ID NO:120, and wherein

(i) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:27, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:87, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:88, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 89, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:90, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:91;

(ii) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:33, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:92, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:88, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 89, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:90, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:91;

(iii) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:27, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:93, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:88, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 89, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:90, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:91;

(iv) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:36, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:87, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:88, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 89, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:90, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:91; or

(v) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:37, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:94, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:95, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 96, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:97, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:98; or

(c) the VH comprises the VH-CDR1, the VH-CDR2, and the VH-CDR3 from the amino acid sequence of SEQ ID NO:109; and the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 from the amino acid sequence of SEQ ID NO:110, and wherein

(i) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:11, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:12, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:13, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 14, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:15, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:16;

(ii) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:17, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:18, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:13, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 14, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO: 15, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO: 16;

(iii) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:11, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO: 19, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:13, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 14, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO: 15, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:16;

(iv) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:20, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:12, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO: 13, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 14, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:15, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:16; or

(v) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:21, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:22, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:23, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 24, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:25, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:26; or

(d) the VH comprises the VH-CDR1, the VH-CDR2, and the VH-CDR3 from the amino acid sequence of SEQ ID NO: 113; and the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 from the amino acid sequence of SEQ ID NO:114, and wherein

(i) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:43, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:44, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:45, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 46, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:47, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:48;

(ii) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:49, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:50, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:45, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 46, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:47, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:48;

(iii) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:43, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:51, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:45, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 46, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:47, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:48;

(iv) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:52, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:44, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:45, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 46, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:47, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:48; or

(v) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:53, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:54, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:55, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 56, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:57, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:58; or

(e) the VH comprises the VH-CDR1, the VH-CDR2, and the VH-CDR3 from the amino acid sequence of SEQ ID NO: 115; and the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 from the amino acid sequence of SEQ ID NO:116, and wherein

(i) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:43, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:59, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:60, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 61, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:62, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:63;

(ii) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:49, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:64, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:60, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 61, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:62, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:63;

(iii) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:43, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:65, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:60, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 61, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:62, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:63;

(iv) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:52, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:59, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:60, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 61, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:62, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:63; or

(v) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:53, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:66, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:67, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 68, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:69, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:70; or

(f) the VH comprises the VH-CDR1, the VH-CDR2, and the VH-CDR3 from the amino acid sequence of SEQ ID NO:121 and the VL comprises the VL-CDR1, the VL-CDR2, and the VL-CDR3 from the amino acid sequence of SEQ ID NO: 122, and wherein

(i) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:71, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:99, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:73, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 100, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:75, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:76;

(ii) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:77, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:101, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:73, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 100, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:75, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:76;

(iii) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:71, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:102, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:73, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 100, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:75, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:76;

(iv) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:80, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO:99, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:73, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 100, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:75, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:76; or

(v) the VH-CDR1 comprises the amino acid sequence of SEQ ID NO:81, the VH-CDR2 comprises the amino acid sequence of SEQ ID NO: 103, the VH-CDR3 comprises the amino acid sequence of SEQ ID NO:83, the VL-CDR1 comprises the amino acid sequence of SEQ ID NO: 104, the VL-CDR2 comprises the amino acid sequence of SEQ ID NO:85, and the VL-CDR3 comprises the amino acid sequence of SEQ ID NO:86.

3. The binding agent of claim 1 , wherein:

(a) the VH comprises the amino acid sequence of SEQ ID NO:117, and/or the VL comprises the amino acid sequence of SEQ ID NO:118;

(b) the VH comprises the amino acid sequence of SEQ ID NO:119, and/or the VL comprises the amino acid sequence of SEQ ID NO:120;

(c) the VH comprises the amino acid sequence of SEQ ID NO:109, and/or the VL comprises the amino acid sequence of SEQ ID NO:110;

(d) the VH comprises the amino acid sequence of SEQ ID NO:113, and/or the VL comprises the amino acid sequence of SEQ ID NO:114;

(e) the VH comprises the amino acid sequence of SEQ ID NO:115, and/or the VL comprises the amino acid sequence of SEQ ID NO:116; or

(f) the VH comprises the amino acid sequence of SEQ ID NO:121, and/or the VL comprises the amino acid sequence of SEQ ID NO:122.

4. The binding agent of claim 1 , wherein:

(a) the VH comprises the amino acid sequence of SEQ ID NO:162, and/or the VL comprises the amino acid sequence of SEQ ID NO:164;

(b) the VH comprises the amino acid sequence of SEQ ID NO:163, and/or the VL comprises the amino acid sequence of SEQ ID NO:164;

(c) the VH comprises the amino acid sequence of SEQ ID NO:156, and/or the VL comprises the amino acid sequence of SEQ ID NO:161;

(d) the VH comprises the amino acid sequence of SEQ ID NO:157, and/or the VL comprises the amino acid sequence of SEQ ID NO:161;

(e) the VH comprises the amino acid sequence of SEQ ID NO:158, and/or the VL comprises the amino acid sequence of SEQ ID NO:161;

(f) the VH comprises the amino acid sequence of SEQ ID NO:159, and/or the VL comprises the amino acid sequence of SEQ ID NO:161; or

(g) the VH comprises the amino acid sequence of SEQ ID NO:160, and/or the VL comprises the amino acid sequence of SEQ ID NO:161.

5. The binding agent of claim 1 , which is

(i) a whole antibody;

(ii) an antibody fragment comprising at least one antigen-binding site;

(iii) a chimeric antibody;

(iv) a recombinant antibody;

(v) a humanized antibody;

(vi) a bispecific or multispecific antibody;

(vii) an IgG1 antibody, an IgG2 antibody, or an IgG4 antibody; or

(vii) attached to a half-life extending moiety.

6. The binding agent of claim 5 , wherein the antibody fragment is a Fab, a Fab′, a F (ab′) 2 , a Fv, an scFv, an (scFv) 2 , a single chain antibody, a dual variable region antibody, a diabody, or a nanobody.

7. The binding agent of claim 1 , comprising

(i) a kappa light chain constant region or a lambda light chain constant region; or

(ii) a human IgG1 constant region and a human kappa light chain constant region.

8. The binding agent of claim 7 , wherein the human IgG1 constant region comprises one or more mutations that reduce or eliminate effector functions.

9. The binding agent of claim 1 , wherein the binding agent has one or more of the following properties:

(i) binding cynomolgus ILT3;

(ii) binding human and cynomolgus ILT3;

(iii) not binding ILT2, ILT4, ILT5, or LILRB5;

(iv) not binding LILRA1, LILRA2, LILRA4, LILRA5, or LILRA6;

(v) being an ILT3 antagonist;

(vi) inhibiting ILT3 activity;

(vii) inhibiting ILT3 signaling in cells that express ILT3;

(viii) inhibiting binding of ILT3 to APOE;

(ix) inhibiting binding of ILT3 to fibronectin;

(x) inhibiting binding of ILT3 to CNTFR;

(xi) inhibiting ILT3-induced suppression of myeloid cells;

(xii) inhibiting ILT3-induced suppression of myeloid cell activity;

(xiii) restoring FcR activation in myeloid cells that express ILT3; and

(xiv) restoring chemokine production in myeloid cells that express ILT3.

10. The binding agent of claim 9 , wherein the binding agent has a K D for human ILT3 of from 1 μM to 1 pM as assessed by Surface Plasmon Resonance (SPR).

11. A pharmaceutical composition comprising the binding agent of claim 1 and a pharmaceutically acceptable carrier.

12. An isolated polynucleotide or polynucleotides encoding the binding agent of claim 1 .

13. A vector or vectors comprising the polynucleotide or polynucleotides of claim 12 .

14. An isolated cell comprising the polynucleotide or polynucleotides of claim 12 , or a vector or vectors comprising the polynucleotide or polynucleotides of claim 12 .

15. A method of making a binding agent that specifically binds human ILT3, the method comprising:

(a) culturing the cell of claim 14 under conditions that result in the expression of the binding agent, and

(b) isolating the binding agent.

16. The method of claim 15 , wherein the method further comprises formulating the binding agent as a sterile pharmaceutical composition.

17. A method of (i) disrupting, inhibiting, or blocking the binding of ILT3 to fibronectin or fibronectin-induced ILT3 activity in a mixture of cells or (ii) disrupting, inhibiting, or blocking ILT3-induced suppression of myeloid cells or ILT3-induced suppression of myeloid cell activity, the method comprising contacting the cells or the myeloid cells with the binding agent of claim 1 .

18. A method of disrupting, inhibiting, or blocking the binding of ILT3 to fibronectin or fibronectin-induced ILT3 activity in a subject, the method comprising administering to the subject a therapeutically effective amount of the binding agent of claim 1 .

19. A method of disrupting, inhibiting, or blocking ILT3-induced suppression of myeloid cells or ILT3-induced suppression of myeloid cell activity in a subject, the method comprising administering to the subject the binding agent of claim 1 in an amount sufficient to activate the myeloid cells.

20. A method of

(i) treating cancer, or inhibiting tumor growth, tumor relapse, or tumor regrowth in a subject,

(ii) increasing or enhancing an immune response to a tumor or tumor cells in a subject, or

(iii) activating myeloid cells in the tumor microenvironment in a subject with a tumor,

the method comprising administering to the subject a therapeutically effective amount of the binding agent of claim 1 .

21. The method of claim 20 , wherein (i) the cancer is pancreatic cancer, breast cancer, lung cancer, head and neck cancer, colorectal cancer, prostate cancer, skin cancer, melanoma, stomach cancer, gastric cancer, intestinal cancer, ovarian cancer, cervical cancer, uterine cancer, endometrial cancer, urinary bladder cancer, brain cancer, esophageal cancer, liver cancer, kidney cancer, sarcoma, or testicular cancer, and/or (ii) the tumor is a pancreatic tumor, a breast tumor, a lung tumor, a head and neck tumor, a colorectal tumor, a prostate tumor, a skin tumor, a melanoma tumor, a stomach tumor, a gastric tumor, an intestinal tumor, an ovarian tumor, a cervical tumor, an uterine tumor, an endometrial tumor, a bladder tumor, a brain tumor, an esophageal tumor, a liver tumor, a kidney tumor, a sarcoma, or a testicular tumor.

22. The method of claim 20 , wherein the cancer is hematologic cancer.

23. The method of claim 22 , wherein the hematologic cancer is myelogenous leukemia, acute myeloid leukemia (AML), chronic myeloid leukemia, or myelodysplastic syndrome.

24. The method of claim 20 , wherein the binding agent is administered as part of a combination therapy comprising a PD-1 antagonist.

25. The method of claim 24 , wherein the PD-1 antagonist is an anti-PD-1 antibody.

26. The method of claim 25 , wherein the anti-PD-1 antibody is pembrolizumab.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2024
From: CRAWLEY, SUZANNE CHRISTINE; HSU, JER-YUAN; KAPLAN, DANIEL DAVID; LI, BETTY CHAN; LIN, VICKY YI-BING; MALMERSJÖ, SETH; PAAVOLA, KEVIN JAMES; RODA, JULIE MICHELLE; WANG, YAN
To: NGM BIOPHARMACEUTICALS, INC.
Reel/Frame 066215/0353 →
Continuity (3)
Division 17125734 · Dec 17, 2020
Provisional Application 62950434 · Dec 19, 2019
Related Publication 20240043533A1 · Feb 8, 2024
References Cited (90)
US 7777008B2 · Ponath et al. · 2010 [cited by applicant]
US 7834157B2 · Cosman · 2010 [cited by applicant]
US 9696312B2 · Suciu-Foca et al. · 2017 [cited by applicant]
US 10428143B2 · Krummel et al. · 2019 [cited by applicant]
US 20040241167A1 · Sucio-Foca et al. · 2004 [cited by applicant]
US 20070041982A1 · Ponath et al. · 2007 [cited by applicant]
US 20070071675A1 · Wu et al. · 2007 [cited by applicant]
US 20070166318A1 · Macina et al. · 2007 [cited by applicant]
US 20090202544A1 · Sucio-Foca et al. · 2009 [cited by applicant]
US 20090226457A1 · Cosman · 2009 [cited by applicant]
US 20090280109A1 · Sucio-Foca et al. · 2009 [cited by applicant]
US 20110034675A1 · Ponath et al. · 2011 [cited by applicant]
US 20150110714A1 · Sucio-Foca et al. · 2015 [cited by applicant]
US 20150139986A1 · Ponath et al. · 2015 [cited by applicant]
US 20150174203A1 · Chen et al. · 2015 [cited by applicant]
US 20160244525A1 · Yin et al. · 2016 [cited by applicant]
US 20170291946A1 · Krummel et al. · 2017 [cited by applicant]
US 20170327591A1 · Sucio-Foca et al. · 2017 [cited by applicant]
US 20180086829A1 · Zhang et al. · 2018 [cited by applicant]
US 20180177847A1 · Chen et al. · 2018 [cited by applicant]
US 20180201676A1 · Blaser et al. · 2018 [cited by applicant]
US 20190153093A1 · Meehl et al. · 2019 [cited by applicant]
US 20190241655A1 · Cua et al. · 2019 [cited by applicant]
US 20190255107A1 · Kuchroo et al. · 2019 [cited by applicant]
US 20220324950A1 · Takai et al. · 2022 [cited by applicant]
DE 3743402A1 · 1988 [cited by applicant]
EP 2041180B1 · 2014 [cited by applicant]
EP 1907001B1 · 2015 [cited by applicant]
EP 2937360A1 · 2015 [cited by applicant]
EP 3265113A2 · 2018 [cited by applicant]
JP S63219393A · 1988 [cited by applicant]
JP 2018025554A · 2018 [cited by applicant]
JP 2008514621A · 2018 [cited by applicant]
WO WO2001077342A1 · 2001 [cited by applicant]
WO WO2003000199A2 · 2003 [cited by applicant]
WO WO2006036813A2 · 2006 [cited by applicant]
WO WO2006036813A3 · 2006 [cited by applicant]
WO WO2014055897A2 · 2014 [cited by applicant]
WO WO2014116846A2 · 2014 [cited by applicant]
WO WO2014179664A2 · 2014 [cited by applicant]
WO WO2016144728A2 · 2016 [cited by applicant]
WO WO2017069958A2 · 2017 [cited by applicant]
WO WO2018022881A2 · 2018 [cited by applicant]
WO WO2018067991A1 · 2018 [cited by applicant]
WO WO2018089300A1 · 2018 [cited by applicant]
WO WO2018148494A1 · 2018 [cited by applicant]
WO WO2018234367A1 · 2018 [cited by applicant]
WO WO2019099597A2 · 2019 [cited by applicant]
WO WO2019144052A1 · 2019 [cited by applicant]
WO WO2019185792A1 · 2019 [cited by applicant]
WO WO2021029318A1 · 2021 [cited by applicant]
Almagro et al., 2008, “Humanitzation of Antibodies”, Front Biosci. 13:1619-1633. [cited by applicant]
Brandish et al., “Antibodies to IL T3 (LILRB4) abrogate myeloid immunosuppression and combine with PD1 blockade to enable T cell activation and function”, Journal for Immuno Therapy of Cancer, 2019, 7(Suppl 1): 283, p. … [cited by applicant]
Carsons, 1987, “High Levels of Fibronectin Fragments in the Plasma of a Patient with Active Systemic Lupus Erythematosus,” The Journal of Rheumatology, 14(5):1052-1054. [cited by applicant]
Cella et al., “A Novel Inhibitory Receptor (IL T3) Expressed on Monocytes, Macrophages, and Dendritic Cells Involved in Antigen Processing”, J. Exp. Med., May 19, 1997, 185(10): 1743-1751. [cited by applicant]
Chen et al., 1995, “Enhancement and destruction of anitbody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial assocations”, EMBO J. 14(12):2784-2794. [cited by applicant]
Condurso et al., 2022, “483. Preclinical Evaluation of JTX-1484, an ANTILILRB4 Antagonist Antibody, for Reprogramming of Immunosuppressive Myeloid Cells”, Journal for Immunotherapy of Cancer, Biomed Central, 10(2):A504. [cited by applicant]
Deng et al., A motif in LILRB2 critical for Angpt12 binding and activation, BLOOD, Aug. 7, 2014, vol. 124, No. 6, pp. 924-935. [cited by applicant]
Deng et al., LILRB4 signaling in leukemia cells mediates T cell suppression and tumor infiltration, Nature. Oct. 2018 ; 562(7728): 605-609. [cited by applicant]
Gribskov et al., “Sigma factors from [cited by applicant]
Gui et al., 2019, “Disrupting LILRB4/APOE interaction by an efficacious humanized 3 antibody reverses T-cell suppression and blocks AML development”, Cancer Immunol Res 1(8):1244-1257. [cited by applicant]
Harakal et al., 2016, “Regulatory T Cells Control Th2-Dominant Murine Autoimmune Gastritis”, J. Immunol 197(1):27-41. [cited by applicant]
International Searching Authority, English translation of International Search Report and Written Opinion for International Patent Application No. PCT/JP2020/030175, Publication No. WO2021029318 A1, mailed Sep. 24, 2020… [cited by applicant]
International Searching Authority, International Search Report and Written Opinion for PCT International Application No. PCT/US2020/065642, Publication No. WO2021127200, mailed Apr. 6, 2021 (21 pages). [cited by applicant]
Kussie et al., 1994, “A single engineered amino acid substitution changes antibody fine specificity”, J. Immunol 152(1):145-152. [cited by applicant]
Lefranc et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains”, Developmental and Comparative Immunology 27 (2003) pp. 55-77. [cited by applicant]
Lu et al., Leukocyte Ig-like Receptor B4 (LILRB4) is a Potent Inhibitor of FcyRI-mediated Monocyte Activation via Dephosphorylation of Multiple Kinases, The Journal of Biological Chemistry, Dec. 11, 2009, 284(50): 34839… [cited by applicant]
Meng et al., 2009, “Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion,” British Journal of Cancer, 101(2):327-334. [cited by applicant]
Mori et al., 2007, “Analysis of differentiation regulation mechanism of human osteoclast cells by LILRB4”, The Journal of Japanese Orthopaedic Surgical Society, 81(8):S980, 1-Pf-2 (in Japanese with machine English trans… [cited by applicant]
Mori et al., 2008, “Inhibitory Immunoglobulin-Like Receptors LILRB and PIR-B Negatively Regulate Osteoclast Development,:” J. Immunol., 181(7):4742-4751. [cited by applicant]
NCBI Reference Sequence: XP _015297198.1, “Leukocyte immunoglobulin-like receptor subfamily B member 4 isoform X1 [Macaca fasscicularis]”, Jan. 25, 2016. [cited by applicant]
Paavola et al., 2021, “The Fibronectin-ILT3 Interaction Functions as a Stromal Checkpoint that Suppreses Myeloid Cells”, Cancer Immunology Research 9:1283-1297. [cited by applicant]
Penna et al., “Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3”, Blood, 2005, 106(10):3490-3497. [cited by applicant]
Przybysz et al., 2013, “Fibronectin molecular status determination useful to differentiate between rheumatoid arthritis and systemic lupus erythematosus patients,” Rheumatol Int., 33(1):37-43 (Epub 2012). [cited by applicant]
Przybysz et al., 2007, “Synovial fibronectin fragmentation and domain expressions in relation to rheumatoid arthritis progression,” Rheumatology, 46(7):1071-1075. [cited by applicant]
Resources.rndsystems.com, “Human LILRB4/CD85k/ILT3 Antibody,” Monoclonal Mouse IgG2A Clone # 293623, Catalog No. MAB24251, Feb. 7, 2018. [cited by applicant]
Rudikoff et al., 1982, “Single amino acid substitution altering antigen-binding specificity”, Proc Natl Acad Sci USA 79(6):1979-1983. [cited by applicant]
Sekiguchi et al., 1983, “Differences in domain structure between pericellular matrix and plasma fibronectins as revealed by domain-specific antibodies combined with limited proteolysis and S-cyanylation: A preliminary n… [cited by applicant]
Stahl et al., “The Tripartite CNTF Receptor Complex: Activation and Signaling Involves Components Shared with Other Cytokines”, Journal of Neurobiology, 1994, 25(11): 1454-1466. [cited by applicant]
Su et al., 2021, “Blockade of checkpoint, ILT3/LILRB4/gp49B binding to fibronectin ameliorates autoimmune disease in BXSB/Yaa mice”, International Immunology 33(8):447-458. [cited by applicant]
UniProtKB/Swiss-Prot: P02751.4, ID: FINC_HUMAN, Dec. 5, 2018. [cited by applicant]
UniProtKB/Swiss-Prot: P26992.2, ID: CNTFR_HUMAN, Dec. 5, 2018. [cited by applicant]
UniProtKB/Swiss-Prot: Q8NHJ6.3, ID: LIRB4_HUMAN, Sep. 12, 2018. [cited by applicant]
Wong et al., 2019, “Gp49B is a pathogenic marker for autoantibody-producing plasma cells in lupus-prone BXSB/Yaa mice”, International Immunology 31(6):397-406. [cited by applicant]
Wu et al., 1999, “Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues”, J Mol Biol 294(1):151-162. [cited by applicant]
Xu et al., 2018, “ILT3.Fc-CD166 Interaction Induces Inactivation of p70 S6 Kinase and Inhibits Tumor Cell Growth,” The Journal of Immunology, 200(3):1207-1219 and Supplemental Material (15 pages). [cited by applicant]
Badri et al., 2015, “Optimization of radiation dosing schedules for proneural glioblastoma,” J. Math. Biol. pp. 1-36. [cited by applicant]
Baylot et al., 2017, “TCTP has a Crucial Role in the Different Stages of Prostate Cancer Malignant Progression,” Spring International Publishing AG 2017, Chapter 13, 255-261. [cited by applicant]
Keskinov et al., 2016, “Pathophysiology of Dendritic Cells in Cancer,” Russian Journal of Biotherapy 15:25-33. [cited by applicant]
Muller et al., 2008, “Spliceosomal Peptide P140 for Immunotherapy of Systemic Lupus Erythematosus,” Arthritis & Rheumatism 58(12):3873-3883. [cited by applicant]